Please login to the form below

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe

In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA treatment. We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance. 

There’s no doubt that the cheaper cost of biosimilars versus their originator biologic, even though not as substantial as generics, make them very attractive to healthcare markets. But so far, biosimilar manufacturers have dedicated most of their efforts to convincing payers of these cost benefits, seeing them as the primary gatekeeper of market access. However, by focusing just on payers, are they missing a trick? In the longer-term, manufacturers could benefit from educating and winning over a wider audience, and not just physicians, but also patients...

25th January 2017



Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Chester House
Fulham Green
81-83 Fulham High Street
United Kingdom